Latest Breaking News On - Presentation title - Page 1 : comparemela.com

TG Therapeutics Announces Schedule of Upcoming Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the 2024 Consortium of Multiple Sclerosis Centers Annual Meeting

TG Therapeutics Announces Schedule of Upcoming Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the 2024 Consortium of Multiple Sclerosis Centers Annual Meeting
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesSan franciscoUnited kingdomStanford universityRiley boveLawrence steinmanSclerosis international federationPediatrics at stanford universityExchange commissionGlobe newswire tg therapeutics incTg therapeutics incWeill institute of neurosciencesNational multiple sclerosis societyDrug administrationHealthcare products regulatory agencyConsortium of multiple sclerosis centers

Candel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of CAN-2409 for Advanced Non-Small Cell Lung Cancer (NSCLC) in Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment at 2024 ASCO Annual Meeting

Median overall survival of 20.6 months was observed following two administrations of CAN-2409 + valacyclovir in NSCLC patients with progressive disease despite immune checkpoint inhibitor therapy.

United statesMccormick placeTheodore jenkinsLeslyem heislerKyle evansCharu aggarwalCompany nasdaqBusiness developmentExchange commissionAmerican society of clinical oncologyPerelman school of medicineDrug administrationUniversity of pennsylvaniaMccormick place convention centerCandel therapeutics incClinical oncology

Protagonist Therapeutics Announces Oral Presentation on Long-Term Follow-up of Rusfertide Phase 2 RE

NEWARK, CA / ACCESSWIRE / May 14, 2024 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or the "Company") today announced that additional data from the rusfertide Phase 2 REVIVE open label extension study will be the focus of an oral presentation at the European Hematology Associatio.

Ann arborUnited statesHall goyaKristenm pettitCorey davisDivision of hematology oncologyDepartment of internal medicineNetwork of companiesUniversity of michiganEuropean hematology associationProtagonist therapeutics incProtagonist therapeuticsPresentation titleUpdated long term resultsStudy investigatingHepcidin mimetic rusfertide

Protagonist Therapeutics Announces Oral Presentation on Long-Term Follow-up ...

Protagonist Therapeutics Announces Oral Presentation on Long-Term Follow-up ...
pr-inside.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pr-inside.com Daily Mail and Mail on Sunday newspapers.

United statesAnn arborHall goyaKristenm pettitCorey davisUniversity of michiganVirginia amannentente network of companiesDepartment of internal medicineDivision of hematology oncologyNews networkProtagonist therapeutics incEuropean hematology associationProtagonist therapeuticsOral presentation titleUpdated long term resultsStudy investigating

Protagonist Therapeutics, Inc.: Protagonist Therapeutics Announces Oral Presentation on Long-Term Follow-up of Rusfertide Phase 2 REVIVE Study Open Label Extension at the European Hematology Association 2024 Congress

Protagonist Therapeutics, Inc.: Protagonist Therapeutics Announces Oral Presentation on Long-Term Follow-up of Rusfertide Phase 2 REVIVE Study Open Label Extension at the European Hematology Association 2024 Congress
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesAnn arborHall goyaKristenm pettitCorey davisDepartment of internal medicineDivision of hematology oncologyProtagonist therapeutics incUniversity of michiganEuropean hematology associationNetwork of companiesProtagonist therapeuticsPresentation titleUpdated long term resultsStudy investigatingHepcidin mimetic rusfertide